Mark Yarchoan, MD, Johns Hopkins Medicine

Locoregional Treatment Strategies in Early-/Intermediate-Stage HCC Locoregional Treatment Strategies in Early-/Intermediate-Stage HCC

Early-Stage HCC: What is the Role of Neoadjuvant Therapy?

Tanios Bekaii-Saab, MD;Anthony B. El-Khoueiry, MD;Pierre Gholam, MD;Arndt Vogel, MD;Mark Yarchoan, MD, Johns Hopkins Medicine

July 6th 2022

Expert oncologists consider when it would be appropriate to use neoadjuvant therapy for early-/intermediate-stage hepatocellular carcinoma.

Early-Stage HCC: Role of Adjuvant Therapy

Tanios Bekaii-Saab, MD;Anthony B. El-Khoueiry, MD;Pierre Gholam, MD;Arndt Vogel, MD;Mark Yarchoan, MD, Johns Hopkins Medicine

June 29th 2022

A brief discussion on the risks of neoadjuvant immunotherapy in early-/intermediate-stage HCC with regard for liver transplantation candidacy.

Patient Profile 1: Resection for Early/Intermediate Stage HCC

Tanios Bekaii-Saab, MD;Anthony B. El-Khoueiry, MD;Pierre Gholam, MD;Arndt Vogel, MD;Mark Yarchoan, MD, Johns Hopkins Medicine

June 29th 2022

Centering discussion on a patient with early/intermediate-stage HCC, expert panelists consider the roles of transplant, resection, and adjuvant therapy, respectively.

Mark Yarchoan, MD, of Johns Hopkins Medicine

Dr. Yarchoan on Unique Characteristics of Fibrolamellar Carcinoma

Mark Yarchoan, MD, Johns Hopkins Medicine

October 22nd 2021

Mark Yarchoan, MD, discusses unique characteristics of fibrolamellar carcinoma.

Optimizing Precision Medicine in HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

October 1st 2021

Takeaways from a discussion on treatment advances in hepatocellular carcinoma.

Biomarkers to Guide HCC Treatment Decisions

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

October 1st 2021

Professionals who treat patients with hepatocellular carcinoma comment on the need for more research and biomarkers to fuel treatment decisions.

Second-Line Treatment Approaches for Advanced HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

September 24th 2021

An overview of the second-line treatment landscape for patients with advanced hepatocellular carcinoma and considerations regarding the sequencing of novel therapies.

The COSMIC-312 Study in Advanced HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

September 24th 2021

Thoughts regarding the COSMIC-312 study of cabozantinib plus atezolizumab as frontline therapy for advanced hepatocellular carcinoma.

HCC: IO in Liver Transplant Recipients

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

September 17th 2021

A debate regarding the appropriateness of immunotherapy following liver transplantation in patients with hepatocellular carcinoma.

The LEGACY Study in HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

September 17th 2021

Implications on treatment practices of the LEGACY study of Y-90 glass microspheres in patients with unresectable solitary hepatocellular carcinoma.

Selecting First-Line Therapy for Advanced HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

September 10th 2021

An overview of factors that deem patients appropriate for atezolizumab/bevacizumab vs lenvatinib or sorafenib as frontline therapy for advanced hepatocellular carcinoma.

Frontline IO for Advanced HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

September 10th 2021

Considerations regarding the use of nivolumab as frontline treatment for advanced hepatocellular carcinoma.

Systemic Treatment Advances for Advanced HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

September 3rd 2021

Exciting developments using novel therapies as systemic treatment for advanced hepatocellular carcinoma.

Scoring/Classifying Patients With Advanced HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

September 3rd 2021

Best practices using available scoring systems to evaluate and treat patients with advanced hepatocellular carcinoma.

Adjuvant Treatment Advances in Operable HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

August 27th 2021

Perspectives regarding treatment advances using adjuvant approaches that include immunotherapy to treat early-stage hepatocellular carcinoma.

Hepatic Arterial Infusion Chemotherapy for HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

August 27th 2021

Reactions to recent clinical abstracts that support the use of hepatic arterial infusions for chemotherapy delivery in hepatocellular carcinoma.

Neoadjuvant Therapy to Downstage HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

August 20th 2021

Reactions to treatment gaps in the neoadjuvant space for hepatocellular carcinoma and implications for incorporating data supporting newer, novel systemic therapies for appropriate patients.

Advances in Locoregional Therapy for Early Stage HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

August 20th 2021

University of Arizona’s Rachna Shroff, MD, describes the role of systemic therapy with locoregional treatment for early stage hepatocellular carcinoma and highlights treatment strategies of interest that remain under investigation.

Current Role of Locoregional Therapy for Early Stage HCC

Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic;Edward Kim, MD, Mount Sinai Medical Center;Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center;Amit Singal, MD, UT Southwestern Medical Center;Rachna Shroff, MD, University of Arizona;Arndt Vogel, MD, Hannover Medical School;Mark Yarchoan, MD, Johns Hopkins Medicine

August 13th 2021

Edward Kim, MD, of Mount Sinai Health System describes where advances in locoregional therapy for early-stage hepatocellular carcinoma fit into the therapeutic landscape.